a public good project by the
Synthesis
Company
of California

© 2026

Anton I. Rosenbaum | doi.page

0 works0 citations0 h-index

Anton I. Rosenbaum

AstraZeneca (Singapore)(SG)AstraZeneca (Brazil)(BR)AstraZeneca (United States)(US)

Publications by Year

Research Areas

HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Biosimilars and Bioanalytical Methods

Most-Cited Works

→ Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells(2010)263 cited
→ Niemann‐Pick type C disease: molecular mechanisms and potential therapeutic approaches(2010)232 cited
→ The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans(2022)212 cited
→ Enzyme-linked immunoassay for detection of PCR-amplified DNA of legionellae in bronchoalveolar fluid(1995)129 cited
→ First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer(2021)85 cited
→ Thiadiazole Carbamates: Potent Inhibitors of Lysosomal Acid Lipase and Potential Niemann−Pick Type C Disease Therapeutics(2010)85 cited

→ Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease(2021)

72 cited

→ Chemical screen to reduce sterol accumulation in Niemann–Pick C disease cells identifies novel lysosomal acid lipase inhibitors(2009)58 cited

→ Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305(2022)56 cited

→ Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2(2019)55 cited